trending Market Intelligence /marketintelligence/en/news-insights/trending/4FZsk6Gstn9XXibtnlE9Ng2 content esgSubNav
In This List

Incyte secures rights to Calithera cancer drug in multimillion dollar deal

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Incyte secures rights to Calithera cancer drug in multimillion dollar deal

Incyte Corp. secured the rights to Calithera BioSciences Inc.'s CB-1158 cancer drug for an upfront payment of $45 million.

Incyte is also investing $8 million in Calithera by purchasing the company's shares at $4.65 apiece.

The agreement gives Incyte the rights to develop and commercialize CB-1158 arginase inhibitor in hematology and oncology. Incyte will fund 70% of the global development costs, with the remaining 30% coming from Calithera.

Calithera will also receive a share of the profits as well as over $430 million in potential milestone-related payments. The agreement provides for Calithera to opt out of its co-funding obligations by foregoing its U.S. profits eligibility.

Calithera will then be eligible to receive up to $750 million in milestone-related payments in such a scenario.

The transaction is expected to close in the first quarter of 2017.